Biomea Fusion, Inc. (BMEA)

US — Healthcare Sector
Peers: EWTX  HOWL  CGEM  DSGN  IKNA 

Automate Your Wheel Strategy on BMEA

With Tiblio's Option Bot, you can configure your own wheel strategy including BMEA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BMEA
  • Rev/Share 0.0333
  • Book/Share 0.7846
  • PB 2.4344
  • Debt/Equity 0.2758
  • CurrentRatio 2.2549
  • ROIC -3.62

 

  • MktCap 71762902.0
  • FreeCF/Share -3.1086
  • PFCF -0.6303
  • PE -0.704
  • Debt/Assets 0.144
  • DivYield 0
  • ROE -1.5273

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed BMEA Piper Sandler -- Overweight -- $7 June 3, 2025
Upgrade BMEA Rodman & Renshaw Neutral Buy -- $18 Sept. 27, 2024
Upgrade BMEA Truist Hold Buy -- $54 Sept. 27, 2024
Initiation BMEA CapitalOne -- Overweight -- $25 Aug. 29, 2024

News

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
BMEA
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive

Biomea Fusion (BMEA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
BMEA
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025).

Read More
image for news Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

About Biomea Fusion, Inc. (BMEA)

  • IPO Date 2021-04-16
  • Website https://biomeafusion.com
  • Industry Biotechnology
  • CEO Dr. Michael J. M. Hitchcock Ph.D.
  • Employees 79

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.